The Technology Gap in GMP Audit Programmes
Pharmaceutical quality assurance has always been a documentation-intensive discipline, but the tools with which that documentation is managed have evolved unevenly across the industry. In manufacturing and laboratory operations, technology adoption ha…
What Audit Findings Tell You About Your Organisation
Audit findings are more than a compliance report card. They are a diagnostic signal, revealing where an organisation’s quality management system is under stress, where process discipline is inconsistent, and where regulatory risk is ac…
The Compliance Challenge Is Not Proportional to Size
Regulatory expectations for Good Manufacturing Practice do not scale with the size of a pharmaceutical company. A small manufacturer or contract development organisation operating under MHRA, FDA, or EMA oversight faces essentially the same …
Why Risk Is the Right Framework for GMP Auditing
Most pharmaceutical and life sciences organisations treat GMP audits as compliance exercises: a scheduled review, a checklist, a report. That approach is not wrong, but it is increasingly insufficient. Regulatory bodies have moved well beyond th…
Introduction
A successful WDA inspection is rarely the result of last-minute polishing. It is usually the visible outcome of deeper operational discipline. Inspectors do not simply assess whether a business has documents, tidy shelves, and a prepared host. They assess whether the organisation …
Introduction
Securing a WDA licence is often treated as the finish line. In reality, it is the point at which the real compliance burden begins. Approval confirms that the licensing authority was satisfied at the time of assessment, but it does not reduce the organisation’s obligations after…
We use cookies to improve user experience and analyse website traffic. By clicking “Accept“, you agree to our website's cookie use as described in our Cookie Policy.
